Is Longer-Term Psychodynamic Psychotherapy More Effective than Shorter-Term Therapies? Review and Critique of the EvidenceBhar S.S.a · Thombs B.D.b · Pignotti M.c · Bassel M.b · Jewett L.b · Coyne J.C.d · Beck A.T.d
aSwinburne University of Technology, Hawthorn, Vic., Australia; bMcGill University and Jewish General Hospital, Montréal, Qué., Canada; cFlorida State University, Tallahassee, Fla., and dUniversity of Pennsylvania, Philadelphia, Pa., USA Corresponding Author
Sunil S. Bhar
Faculty of Life and Social Sciences, Swinburne University of Technology
Mail H24, PO Box 218
Hawthorn, Vic. 3122 (Australia)
Tel. +61 3 9214 8371, Fax +61 3 9214 5898, E-Mail firstname.lastname@example.org
Background: In 2008, Leichsenring and Rabung performed a meta-analysis of 8 studies of longer-term psychodynamic psychotherapy (LTPP). The work was published in the Journal of the American Medical Association (vol. 300, pp 1551–1565), and they concluded that LTPP was more effective than shorter-term therapies. Method: Given that such claims have the potential to influence treatment decisions and policies, we re-examined the meta-analysis and the 8 studies. Results: We found a miscalculation of the effect sizes used to make key comparisons. Claims for the effectiveness of LTPP depended on a set of small, underpowered studies that were highly heterogeneous in terms of patients treated, interventions, comparison-control groups, and outcomes. LTPP was compared to 12 types of comparison-controls, including control groups that did not involve any psychotherapy, short-term psychodynamic psychotherapy, and unvalidated treatments. Additionally, the studies failed to protect against threats to bias, and had poor internal validity. Conclusion: Overall, we found no evidence to support claims of superiority of LTPP over shorter-term methods of psychotherapy.
© 2010 S. Karger AG, Basel
Evidence for the relative effectiveness of psychodynamic treatments is mixed . Flawed study methodologies may at least partially explain inconsistencies in reported findings. The authors of a recent review found ‘not a single well-done randomized controlled trial of dynamic therapy’ for most mental health disorders [, p. 103]. Yet, a recent meta-analysis by Leichsenring and Rabung  concluded that longer-term psychodynamic psychotherapy (LTPP), defined as lasting at least 1 year or 50 sessions, was ‘significantly superior to shorter-term methods of psychotherapy with regard to overall outcome, target problems, and personality functioning’ (p. 1563). This claim was based on 8 small studies [3,4,5,6,7,8,9,10]1 that compared LTPP to various control conditions across a diverse range of outcomes.
In an accompanying editorial, Glass  declared the meta-analysis to be a ‘carefully performed’ (p. 1589) defense against criticisms that LTPP lacked empirical support. The meta-analysis has now also been cited as evidence for the effectiveness of psychodynamic treatments , and referenced in draft guidelines for empirically supported treatments for depression .
An uncritical acceptance of the conclusions of meta-analyses is common [14,15]. However, as demonstrated by Sensky , many meta-analyses are not rigorous and can obscure variations in treatment outcomes across research trials. Failure to adequately specify research questions in systematic reviews can result in ‘spurious groupings of data from differing individual studies’ [, p. 132] that do not reflect the efficacy or effectiveness of any specific therapeutic intervention for any particular patient group. Thus, calls have been made for rigorous scrutiny of meta-analyses, including the quality of evidence from individual studies, the degree of clinical heterogeneity in samples, control conditions and outcomes and the methods used to generate aggregate effect sizes [17,18,19,20].
Brief post-publication letters [21,22,23,24] highlighted serious problems with Leichsenring and Rabung’s  meta-analysis. In this article, we examine in greater detail the validity of its conclusions. First, we consider the methods employed to aggregate and compare effect sizes across studies. Second, we examine the statistical power and heterogeneity of patients treated, interventions applied and outcomes of reviewed studies. Finally, we assess the risk of bias in the individual studies. Although our critique focuses on one specific meta-analysis, it highlights the types of issues that need to be taken into account when interpreting findings of meta-analyses of comparative outcome studies.
Leichsenring and Rabung  calculated separate within-group pre-post effect sizes for LTPP and comparison groups. They then erroneously calculated point biserial correlations of group (LTPP vs. comparison) and within-group effect sizes. This departed from standard methods where between-group effect sizes are presented as standardized group differences in treatment outcome scores between the 2 groups or as point biserial correlations between group (e.g. LTPP vs. shorter-term therapies) and outcome scores. Standardized mean difference and correlational metrics are essentially equivalent and convertible using simple formulae or tables . Leichsenring and Rabung apparently used a conversion formula intended for conversions of between-group point biserial correlations to standardized difference effect sizes in an attempt to convert their correlations of group and within-group pre-post effect sizes into deviation-based effect sizes. As a result, even though none of the 8 studies reported an overall standardized mean difference greater than 1.45 [, see fig. 2 on p. 1558], the authors reported a combined effect size of 1.8. Similarly, these methods generated an implausible between-group effect size of 6.9, equivalent to 93% of variance explained, for personality functioning based on 4 studies [3,5,6,26]2, none of which reported an effect size more than approximately 2.
Table 1 shows results from a hypothetical meta-analysis to illustrate the computational error. In 9 of the 10 studies in table 1, the pre-post effect size for the treatment group was 0.10 larger than the effect size for the control group. In the tenth study, the effect size was 0.09 larger. Despite minimal differences in pre-post treatment effects, the method employed by Leichsenring and Rabung  generates a correlation between pre-post effect size and group of 0.999 and an implausibly large deviation-based effect size of 46.7. Thus, rather than realistic estimates of the comparative effects of LTPP, Leichsenring and Rabung based their meta-analysis on grossly incorrect calculations.
Beyond the issue of statistical aggregation, it is important to ask whether a set of studies can meaningfully be summarized by a single effect estimate . Two factors are important to consider: (1) the extent to which the global effect size estimates depend on small, underpowered studies, and (2) the clinical heterogeneity of the patients, interventions, and outcomes.
Leichsenring and Rabung  argued that publication bias was absent on the basis of rank correlations between effect size and sample size. However, a non-significant test cannot rule out publication bias, particularly in small meta-analyses with only a few studies included . With only 8 studies being considered, the exercise of calculating such correlations becomes meaningless because nonsignificant results are virtually foreordained.
Kraemer et al.  have further shown that inclusion of small, underpowered trials in meta-analyses results in substantially overestimated pooled effect sizes, due to a confirmatory publication bias for which statistical correction is not possible. Kraemer [pers. commun., 2008] proposed that trials included in meta-analyses should have at least a 0.70 probability of detecting a moderate size effect (e.g. δ = 0.50), which would require at least 50 patients per group. The 8 studies pooled by Leichsenring and Rabung  had between 15 and 30 patients in the LTPP treatment group, with power to find a moderate effect size ranging between 0.23 and 0.48 (table 2). With the assumption that few investigators would attempt to publish negative studies with such small samples and that few journals would likely accept them for publication, these studies would have had to have an effect size of at least 0.50 to 0.75, the minimum for statistical significance in order to be published and available for review. This guarantees a spurious large effect even when a treatment lacks efficacy.
Anticipating the likely statistical heterogeneity in the studies being considered, Leichsenring and Rabung  used a random effects model for analyses. These models, however, are not capable of compensating for considerable clinical heterogeneity in terms of control-comparison groups, diagnoses and outcome measures.
Heterogeneity of Control-Comparison Conditions. The 12 different comparison-control conditions deemed ‘shorter-term methods of psychotherapy’ included empirically supported treatments, such as dialectic behavior therapy, but also conditions such as waitlist control condition, nutritional counseling, standard psychiatric care, low contact routine treatment, treatment as usual in the community, referrals to alcohol rehabilitation and provision of a therapist phone number (table 3). In one study, the authors explicitly stated that participants in the ‘control group received no formal psychotherapy’ [, p. 1565]. To put these control conditions under the umbrella of ‘shorter-term methods of psychotherapy’ [, p. 156] is misleading. Even among the studies that compared LTPP to psychotherapy, considerable heterogeneity was evident in the comparison-controls. In only 2 studies was LTPP compared to an empirically supported treatment, as defined by Chambless and Hollon , that is, dialectic behavior therapy for borderline personality disorder , and family therapy for anorexia nervosa . In 2 other studies, LTPP was compared to cognitive therapy  and short-term psychodynamic psychotherapy , which are established as efficacious for some disorders, but not yet validated for the disorder being treated (i.e. cluster C personality disorders, ‘neurosis’). In a fifth study , LTPP was compared to ‘cognitive orientation therapy’, an unvalidated treatment. In these original studies, statistical superiority of LTPP over control conditions was found only when control conditions involved either no psychotherapy, or an unvalidated treatment. Studies that compared LTPP to an empirically supported (e.g. dialectic behavior therapy, family therapy) or established treatment (e.g. short-term psychodynamic psychotherapy, cognitive therapy) found that LTPP was equally or less effective than these treatments despite a substantially longer treatment period.
Heterogeneity of Diagnoses. The samples in these studies were heterogeneous in terms of patient diagnoses. Across the 8 studies, LTPP was compared to other interventions for a total of 9 types of mental health problems, including ‘neurosis’ , ‘self-defeating personality disorder’  and anorexia nervosa [5,7] (table 3). This is akin to asking whether one type of medication is superior to another for all types of physical illnesses . As recommended by Chambless and Hollon , treatment outcome research should ‘not ask whether a treatment is efficacious; rather [...] whether it is efficacious for a specific problem or population’ (p. 9). A clinician could not determine from the global effect sizes published by Leichsenring and Rabung  whether to expect a patient with an eating disorder or with Borderline Personality Disorder, for instance, to benefit from LTPP. For that information, a clinician would have to return to the original studies, which were too small and methodologically weak to offer much guidance.
Heterogeneity of Outcomes. The number of outcomes in the 8 studies ranged from two  to twelve . The standard practice of selecting a single primary outcome measure may be difficult to accomplish in complex interventions, such as psychotherapy . Nonetheless, combining all outcomes reported in a given dimension and then considering each dimension equally in producing a single study effect size was poorly justified and resulted in questionable estimates of effect sizes. Specifically, Leichsenring and Rabung  classified each measure as an indicator of 1 of 4 dimensions: target problems, symptoms, social functioning, or personality. They then averaged the effect size of all measures within each dimension to obtain a dimension effect size. From there, they averaged dimension effect sizes to obtain a single global effect size for a study. One study , for example, reported 2 outcome measures of target problems, one with an extremely large effect size of 1.46, and the other with a negligible effect size of 0.17. These were apparently averaged to obtain a single large effect size of 0.82. This effect size of 0.82 for target problems was then averaged with an effect size of essentially zero (0.01) for the symptoms dimension, and a very large effect size of 1.13 for the personality dimension to produce a global effect size of 0.65 that was not representative of any of the individual effect size estimates for any of the outcomes.
The validity of a meta-analysis is limited by the quality of evidence provided by the individual studies. As stated by Chambless and Hollon , it is ‘unwise to rely on meta-analyses unless something is known about the quality of studies that have been included and there is confidence in the data.’ (p. 13). Leichsenring and Rabung  assessed the quality of studies with a modified version of the Jadad scale  and found no significant association between the total score on this 3-item scale and post-treatment effect sizes. They concluded that study quality was not related to effect sizes.
This approach was problematic for 3 reasons. First, single quality scores are known to be unreliable and their use is not supported by empirical evidence. Second, the Jadad scale is not designed as a generic measurement of study quality, but rather emphasizes completeness of reporting, and therefore would not be expected to discriminate between studies or identify poorly designed studies. For example, it does not cover one of the most important potential biases in randomized trials, namely allocation concealment . Third, relying on correlations between the total score of such scales and effect sizes is not informative about the overall quality of evidence proffered by the sample of studies ; the lack of association may reflect problems such as poor statistical power or restricted range when many poor-quality studies are combined. Rather than the methods used by Leichsenring and Rabung, the quality of evidence is best assessed by examining whether comprehensive procedures were in place to protect against specific sources of bias .
The Cochrane Collaboration’s tool  addresses 6 sources of bias: methods of sequence generation; procedures for concealing allocations of participants to conditions; whether blinding of assessors or participants was established; completeness in outcome data; omissions in reporting outcomes, and other sources of potential bias (e.g. imbalance between interventions, poor treatment integrity). Following the Cochrane guidelines, we evaluated the risk of bias in each of the 8 studies sampled by Leichsenring and Rabung  and applied a rating of ‘Yes’, ‘No’ or ‘Unclear’ to denote whether adequate measures were taken to protect against each potential source of bias in each study, with ‘Yes’ indicating that such measures were taken, ‘No’ that they was not, and ‘Unclear’ indicating insufficient information. Two investigators independently assessed each article and inconsistencies were resolved by consensus. Inter-rater agreement was high for pre-consensus ratings. Of the 56 ratings shown in table 4 (assessment of risk of bias, except for treatment integrity), 52 (94.6%) were matched between raters (Cohen’s kappa = 0.92). Of the 64 ratings of treatment integrity procedures in table 5 (assessment of treatment integrity), 58 (90.6%) were initially matched between raters (Cohen’s kappa = 0.80).
As shown in table 4, only 2 of the 8 studies identified methods of randomization [4,7]. Two studies clearly did not randomize patients to conditions. In one, patients were not randomly assigned across long- and short-term forms of treatment, but only between individual and group-based versions of the treatment . The other included a non-random waitlist control group . The remaining 4 studies [5,6,8,10] stated that patients were randomly assigned, but did not provide information to determine how this was done.
Adequate concealment of allocation sequence shields those who enroll participants from knowing upcoming assignments. Such knowledge could allow selective enrollment of participants to favor a particular treatment. Piper et al.  successfully concealed the allocation sequences by delaying decisions about assignments until after initial assessments. However, the remaining 7 studies either failed to conceal allocation sequence  or did not provide sufficient information to assess allocation concealment [4,5,6,7,8,10]. For example, Gregory et al.  reported that patients were randomly assigned to outpatient treatment conditions, but did not provide information about measures taken to prevent investigators knowing ahead of time what the assignments would be.
Blinding refers to a process by which study participants and personnel, including raters assessing outcomes, are kept unaware of intervention allocations after enrollment of participants . In psychotherapy research, complete blinding of participants and providers is not possible. However, independent assessment of outcomes by raters blinded to the treatment received can reduce bias.
Blinding was not judged to be a source of bias in 2 studies [8,10] where outcomes were measured through self-report measures. In 3 studies, information was not provided on whether or not outcome assessment was blind [3,5,6]. For example, Bachar et al.  reported that pre- and post-assessment procedures were conducted by the same evaluator, who was not the therapist, but did not specify if the evaluator was blinded to group assignment. In the remaining 3 studies, blindness of outcome evaluators was either not ensured [7,9] or not adequately tested . Guessing group assignment  is an unsatisfactory test of blindness .
Missing outcome data due to drop-outs during treatment or exclusion of enrolled participants from analyses can generate substantially biased effect estimates . Intention-to-treat (ITT) analysis is the recommended standard by which outcome effects should be evaluated in order to avoid this problem . An ITT analysis is conducted on all randomized participants, regardless of whether they completed the intervention, and incomplete outcome data are replaced using imputation strategies. The imputation strategy of last observation carried forward (LOCF) is unsatisfactory because it can artificially inflate or deflate the difference between experimental and treatment groups [35,36].
In table 4, studies were rated relatively low in risk of bias if they employed an ITT analysis and described an optimal strategy for imputing missing data (e.g. growth curve analysis). Studies were rated as having high risk of bias, if they analyzed only those individuals who completed interventions (i.e. ‘completers’ analysis). Studies that used LOCF for imputing missing data or did not describe their imputation strategy were rated as having an unclear level of risk. Only 1 of the 8 studies met criteria for low risk of bias . Two studies were classified as having a relatively high risk of bias, because they analyzed completers only [3,5]. The remaining 5 studies were rated as having an unclear level of risk because they used variants of LOCF to estimate missing data in their ITT analysis [4,7], did not report whether data were missing , or did not describe if and how missing data were estimated [6,8].
Selective outcome reporting refers to reporting a subset of the outcomes, based on the results obtained , such as only reporting statistically significant results. We checked if studies reviewed by Leichsenring and Rabung  were registered (clinicaltrials.gov database, World Health Organization International Clinical Trials Registry Platform). Of the 8 studies we reviewed, the 3 most recent studies could potentially have been registered prior to publication [4,9,10], but only 1 was registered and pre-specified its outcome variables . For the remaining 7 studies, we examined the article for an explicit statement that a priori determined outcomes were reported. One study contained such a statement . For the other 6 studies, the extent to which outcomes were selectively reported remained unclear (table 4).
We next considered the degree to which the included studies protected against bias due to treatment imbalance and treatment integrity.Treatment imbalance refers to uncontrolled differences between how treatments were administered that may have accounted for why 1 treatment was superior to another. Three types of differences were identified between treatment groups: (1) number of sessions and duration of treatment; (2) frequency of sessions per week, and (3) medication augmentation. First, patients in the LTPP condition received on average, 103 sessions over 53 weeks, while those in the comparison conditions received on average, 33 sessions over 39 weeks . Second, 6 of the 8 studies did not control differences in session frequency between conditions. In one study , LTPP consisted of weekly sessions, while family therapy was ‘scheduled by negotiation between once a week and once every 3 weeks’ (p. 217). In another study, patients in LTPP received twice as many sessions per week, compared to those in supportive treatment . Third, confounding concurrent medications were not controlled in 5 of the 8 studies [3,4,5,7,9]. Such omissions preclude evaluation of the independent effect of LTPP.
Treatment integrity, which refers to whether treatments were implemented as intended and whether conclusions about relative efficacy may reflect differential competency in delivery [37,38], was not adequately examined in any of the 8 studies. Assessments of treatment integrity should reflect both whether therapists adhered to treatment protocols (treatment adherence) and the degree to which they delivered treatments competently. Treatment adherence and competence can each be evaluated on 4 domains reflecting how well each aspect was: (1) established (e.g. did therapists use treatment manuals and were they trained to competently administer the treatments?); (2) assessed (e.g. did researchers use sound psychometric measures to assess adherence and competence?); (3) evaluated (e.g. were procedures adopted to minimize therapist reactivity, that is, to minimize the extent to which therapists modify behavior when being observed; were raters reliable?), and (4) reported (e.g. did researchers provide numerical descriptions of levels of adherence or competence?) .
The use of traditional treatment manuals has typically been eschewed by proponents of psychoanalytic treatment  who argue that such manuals constrict that therapeutic approach and thus reduce the effectiveness of the treatment . Nevertheless, 7 of the 8 studies reviewed by Leichsenring and Rabung  employed a manual or manual-like protocol to guide treatment (table 5). However, other gaps in the examination of treatment integrity were found more frequently among the sample of studies. Three studies did not assess treatment adherence [3,7,9], and 4 did not describe procedures to assess therapist competency [3,6,7,9]. None controlled for therapist reactivity, evaluated inter-rater variability, or reported numerical ratings of levels of adherence or competence. Overall, the extent to which treatments were delivered as intended in this sample of studies was poorly documented.
Our examination of Leichsenring and Rabung’s  meta-analysis demonstrates how the failure to attend to important methodological issues can generate invalid conclusions. The most damning threat to the validity of findings in their meta-analysis was their gross miscalculation and aggregation of comparative effect sizes of included studies. Second, the meta-analysis was based on studies with small samples sizes, and overly heterogeneous comparative treatments, disorders and outcomes. Thus, one cannot know if LTPP is superior to other treatments only for certain disorders, but not for others, or for none. Given that treatment integrity was not well examined in most studies, one also cannot know if the delivery of treatments was executed in a competent manner and in the manner described in study treatment protocols. Finally, their conclusion was based on a sample of studies that failed to protect against multiple potential sources of bias, thus producing weak quality evidence.
Our assessment is consistent with Gibbons et al.  who found the literature concerning dynamic therapy to be methodologically weak. Our observations also mirror other commentaries regarding the methodological limitations of meta-analyses [14,16]. Despite the recognition of the importance of strategies to limit bias in the assembly and analysis of primary studies included in meta-analyses , our review of Leichsenring and Rabung’s  study shows that meta-analytic techniques continue to be poorly implemented even in high-impact journals.
There are a number of caveats to our assessment. First, we assessed the risk of bias, rather than the true level of bias in included studies. Second, our assessment of the articles was based on what was reported rather than what was done in the research. Authors of articles were not contacted for information. It is possible that methodological procedures were omitted from the reports or were misrepresented. Third, although our critique covered an extensive range of potential methodological flaws affecting the meta-analysis, other factors were not addressed in this review, such as the reliability of measurements, criteria employed for selecting a study for inclusion into the meta-analysis, and effects of excluding relevant articles. In addition, we did not employ assessment tools such as AMSTAR  to formally evaluate the reporting or methodological quality of the meta-analysis. Therefore, the quality of the meta-analysis as defined by these tools is yet to be investigated.
Our critique highlights the type of problems that can be inherent in meta-analyses and which need to be addressed by researchers employing this research strategy. As meta-analyses become more prominent in the field, specific attention should also be directed towards the quality of evidence, synthesis of the evidence, and statistical methods of aggregating effect sizes. As shown in our review, the failure to adequately attend to each of these potential problems reduces the scientific credibility of meta-analyses. Thus, the question of whether LTPP is more effective than shorter-term psychotherapy remains open. Answering that question would require more rigorous comparative trials than are currently available.
This research was supported by the National Institute of Mental Health (P30 MH45178). Dr. Thombs is supported by a New Investigator Award from the Canadian Institutes of Health Research and an Établissement de Jeunes Chercheurs award from the Fonds de la Recherche en Santé Québec. Ms. Jewett is supported by a Frederick Banting and Charles Best Canadian Graduate Scholarship – Master’s Award from the Canadian Institutes of Health Research. We wish to thank Gloria Huh and Megan Spokas for their assistance in revising the manuscript.
As listed on p. 1559 of .
Levy et al.  analyzed data on personality variables relevant to the outcome study reported by Clarkin et al. .
Sunil S. Bhar
Faculty of Life and Social Sciences, Swinburne University of Technology
Mail H24, PO Box 218
Hawthorn, Vic. 3122 (Australia)
Tel. +61 3 9214 8371, Fax +61 3 9214 5898, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.